NCT02303366View on ClinicalTrials.gov

Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Breast NeoplasmsBone Neoplasms
Interventions
RADIATION

Stereotactic Ablative Body Radiosurgery (SABR)

Stereotactic Ablative Body Radiosurgery (SABR) - a single 20Gy in 1 fraction.

DRUG

MK-3475

MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.

Trial Locations (1)

8006

Peter MacCallum Cancer Centre, Melbourne

All Listed Sponsors
lead

Peter MacCallum Cancer Centre, Australia

OTHER

NCT02303366 - Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 | Biotech Hunter | Biotech Hunter